Evaluating Acceptance of Visible Chronic Skin Conditions
Acceptance Des Maladies Chroniques Dermatologiques Visibles : Constitution d'échelles Pour le Patient et Son Cluster Familial
This study is testing new questionnaires to see how well people of all ages accept visible skin conditions like vitiligo and alopecia areata.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 1 site (Tours) |
| Trial ID | NCT06103903 on ClinicalTrials.gov |
What this trial studies
This study aims to validate four scales designed to assess the acceptance of visible chronic dermatological diseases such as vitiligo, alopecia areata, and port wine stains. It will involve a diverse group of participants, including children, adolescents, and adults, along with their parents, to ensure a comprehensive understanding of disease acceptance across different age groups. Participants will complete a detailed questionnaire consisting of 50-55 items tailored to their age and condition. The study will be conducted in multiple centers to achieve territorial representativeness.
Who should consider this trial
Good fit: Ideal candidates include children aged 6 and older, adults, and parents of children with specific chronic dermatological conditions.
Not a fit: Patients with secondary skin marks or major psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how patients cope with visible chronic skin conditions, potentially leading to improved psychological support and interventions.
How similar studies have performed: While the approach of validating acceptance scales is common, the specific focus on chronic dermatological diseases in a multicentric setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Targeted pathologies: * Flat angioma * Primary hypopigmentation and early vitiligo * Primary hyperpigmentation * Refractory alopecia areata or congenital alopecia 2. Persons concerned: * Children (≥ 6 years old) suffering from one of the aforementioned pathologies * Adults suffering from one of the above-mentioned pathologies * Parents of children suffering from one of the aforementioned pathologies * Parents of young adult patients if they live under the same roof 3. Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor) Exclusion Criteria: 1. Secondary "marks" (post-inflammatory, post-medication, post-traumatic, etc.) 2. Major psychiatric disorders
Where this trial is running
Tours
- University Hospital TOURS — Tours, France (Recruiting)
Study contacts
- Study coordinator: Annabel MARUANI, MD-PhD
- Email: annabel.maruani@univ-tours.fr
- Phone: +33 (0)247479076
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.